Early analysis of Gilead’s experimental drug remdesivir in severe COVID-19 infections has shown a 68% improvement in a group of severely ill patients. The drug is being used in a compassionate setting and there’s no comparison group. The results published by the New England Journal of Medicine are the first in COVID-19 patients for remdesivir.   Of the 53 patients whose data were analyzed, 22 were in the U.S., 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were re...